For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Vyndamax and Attruby represents a significant advancement . These novel therapies preserve the transthyretin protein, preventing its harmful build-up and lessening the impact of the condition . Individuals are now reporting improve